OWC PHARMACEUTICALS RESEARCH OTCQB:OWCP

Size: px
Start display at page:

Download "OWC PHARMACEUTICALS RESEARCH OTCQB:OWCP"

Transcription

1 OWC PHARMACEUTICALS RESEARCH OTCQB:OWCP

2 Disclaimer This document details business information of OWC Pharmaceuticals Research Corp and/or our wholly-owned Israeli subsidiary, One World Cannabis Ltd. (collectively, OWCP, OWC Pharmaceuticals Research Corp, "One World Cannabis ", "OWC" or "the Company") for the development of cannabinoid-based therapies targeting a variety of different medical conditions. The Company s research division is focused on pursuing clinical trials, evaluating the effectiveness of cannabinoids in the treatment of these various medical conditions. This presentation outlines the specific needs and the special opportunities that OWC believes exist in the medical cannabis market together with OWCP s research and development activity to date and the potential target markets for OWC s present and planned products. This presentation also details the Company s business strategy and financial information operation based on certain assumptions, market data, and OWC s opinions. This presentation has been developed in a reasonable and rational manner to reflect OWC s plan setting forth a defined time schedule based partly on known information, and partly on assumptions and forecasts of OWC. However, as with all business plans, its anticipated results are based on information available at the time of preparation, relying on that information s accuracy and reliability, and also based on the specific assumptions made. Changes in the economical and regulatory factors, among others, as well as additional information or various other events, can change the assumptions as well as the results. This presentation itself does not guarantee its partial or full execution. Therefore, it is possible that this business plan will not be fully implemented and executed as planned. Confidential information All information contained herein contains copyrighted information that is proprietary, privileged or confidential. It is intended only for the purpose specified and directed to the recipients specifically identified by the company. Any unauthorized review, disclosure, reproduction, distribution, copying of, or reliance upon this document and any included exhibits is strictly prohibited.

3 One World Cannabis Ltd. One World Cannabis Ltd. was set up in July 2014 in Israel as a Wholly owned subsidiary of OWC Pharmaceutical Research Corp. (OTCQB:OWCP). The state of Israel supports cannabis study and scientific research since the 1960s in renown academic and research hospitals. The Medical Cannabis Unit under the Health Minister Office is operating in Israel since 2003

4 Vision OWC Pharmaceutical aims to become a leader in creating new cannabis-related treatments and devices targeting a variety of diseases and medical conditions, by identifying unique formulation and efficient delivery systems. We are determined to bring the safe messages of clinically tested cannabis treatments by aiding regulators and business groups worldwide through our international division for regulatory affairs

5 Mission R&D Division: All our studies are following an approved clinical procedures by IRB protocols conducted in Israeli hospitals facilities. Each new product targets a specific disease or medical conditions, with a particular focus on identifying unique formulation and efficient delivery systems to optimize the bio-availability of each dosage Consulting Division: Supporting and aiding organizations and states which are on the way to implement MMJ program and are looking to adopt the Israeli MMJ Methodology which includes patients treatments, recommended daily dosage, manufacturing standards, education programs, knowledge transfer to physicians and more.

6 What is Medical Cannabis? Tetrahydrocannabinol (THC) Psychoactive component of cannabis. Medically used for the treatment of epilepsy and other conditions. Isolated in 1964 by Israeli researchers at the Hebrew University in Jerusalem. Cannabidiol (CBD) Non-psychoactive component of cannabis. Medical uses as an anti-inflammatory agent with numerous beneficial qualities

7 Medical Cannabis Market USATODAY: ArcView Market Research and New Frontier, a cannabis-focused data-analysis firm says that by 2020, adult use and medical marijuana sales are expected to reach nearly $23 billion.

8 OWCP Competitive Edge Based in Israel: Cannabis research is supported by the Israeli government, one of the few countries worldwide to approve clinical studies with cannabis Dr. Med. Yehuda Baruch: leading our two divisions as the Chief scientist officer and regulatory affairs, Dr. Baruch, a world renowned Psychiatrist, founded, implemented and Headed the Israeli Medical Cannabis Unit under the Minister of Health for over 10 years.

9 OWCP Products

10 Cannabis Based Products IP-owned developed of new innovative and tested delivery systems. Delivery systems Ready : Sublingual Soluble tablet: replacement of smoking, pain treatment. more than 10 million potential patients in the approved MMJ states. Topical crème: Treatment for different skin diseases starting with tested psoriasis. ~8 Million Psoriasis patients US & Canada (2.5% of population) Fixed and controlled dosage Quality controlled Waiting for safety and clinical results

11 OWCP Active Studies

12 Multiple Myeloma (a cancer of plasma cells) Designed to be an Orphan Disease study approved by the FDA In-vitro study completed 06/2015 Cannabis kills the MM cancer cells Pre-clinic study on mice completed 12/2015 calibration phase for dosage, found most effective ratio of active cannabinoids THC/CBD In-vitro study for a combination of 4 approved drugs with cannabis completed 05/2016 promising results Pre-clinic study for the most effective combination on mice with new cannabis extracts. On-going testing. SUBJECT TO ACHIEVING SCIENTIFIC MILESTONES THE COMPANY WILL SUBMITT AN APPLICATION WITH THE FDA FOR AN ORPHAN DISEASE DESIGNATION

13 Psoriasis (Skin Disease) Pharma-grade challenge tests successfully completed 05/2016 Active Safety study at the biggest academic hospital in Israel, under approved IRB (Helsinki) protocol. In-vitro psoriasis Pre Clinical efficacy study of the topical crème - completed - Up to 70% improvement with inflammation markers directly related to Psoraisis IP owned by OWCP EXPECTED MARKET READINESS : Q3/2017

14 Roadmap Utilizing the existing products for new medical indications Tablets for pain relief: PTSD, Fibromyalgia and Pain (Migraine) Crème for skin diseases: Psoriasis firs with possible Acne, Basal cell carcinoma, Atopic dermatitis and more Developing another new delivery system

15 Strategic Alliances

16 MICHEPRO Ltd. Michepro A European distribution company; Signed a Joint-Venture agreement, 75% (OWCP) 25% (MICHEPRO Ltd); Aim: to set up a European entity to promote, manufacture and sell OWCP products in Europe

17 Accomplishments (since 7/2014): April 2017 Clinical studies: Delivery system: Patents: Two active studies Three systems (Two ready - tablets; cream; One in development) Eight patents

18 Corporate & Financial Details A Delaware corporation, fully SEC reporting company trading in the QB Tier of the OTC market : OWCP:QB Debt free Sufficient funds to complete current 2017 operating and BP Authorized Capital :500,000,000 Outstanding shares: 144,719,287 (31 March 2017) Float: 125,000,000 (31 March 2017)

19 Management Team OWCP management is composed of a highly experienced team of experts in various areas of the medical cannabis, clinical research, healthcare management, international business and financial markets. Mr. Mordechai Bignitz Chairman; CEO of OWC Pharmaceuticals Research Corp. Veteran businessman with 35 years of experience with executive leadership in large international corporations, Including senior positions with Pharma and Biotech companies and the chairman of the biggest investment fund in Israel for 9 Yrs. Dr. Med. Yehuda Baruch CSO, Director of Research and Regulatory Affairs. Former CEO of Abarbanel Mental Health Center in Bat-Yam. The founder of the Israeli Medical Cannabis program and its director for 10 years Mr. Alon Sinai Chief Operating Officer and Interim Chief Executive Officer Retired Lieutenant-Colonel from the IDF Medical Corps. Was responsible for supervising and developing emergency medical facilities Mr. Shmuel De-Saban, CPA CFO, OWCP and One World Cannabis Ltd 19

20 Advisory Team The Advisory Team, which is made up of industry thought-leaders and experts, evaluates the Medical Cannabis market (clinical research; healthcare management; financial data), and provides the Management Team strategic and tactical advice, as well as feedback from an industry and community perspective. Mr. Jeffrey Friedland Advisory Board Member. The author of "Marijuana: The World's Most Misunderstood Plant." He is a regular speaker on the cannabis industry and has been featured or quoted in numerous publications. Mr. Friedland has investments and business involvements in the cannabis industry globally. Dr. Sharon Rozenblat VPSenior Advisor To Scientific Advisory Board Dr. Rozenblat will be tasked with overseeing the completion of the pre-clinical safety studies on the Company s treatment for psoriasis. Dr. Rozenblat will also steer the Company s efforts to commercialize OWC s cannabis-based formulations and delivery mechanisms. Ms. Miri Sani, MSc Eng. Advisory board member. Ms. Sani is the CEO and owner of Shefa Amirim Ltd, which provides regulatory affairs and clinical consultation services for early stage start-ups in various medical fields. Ms. Sani will advise the company s management on the transition of the in-house innovative developed cannabinoids products and delivery systems, to full industrial production, 20

21 For further information: Visit our website - Or contact: Mr. Mordechai Bignitz, Chairman & CEO mordechai.bignitz@owcpharma.com Dr. Yehuda Baruch, CSO yehuda.baruch@owcpharma.com

OWC PHARMACEUTICAL RESEARCH OTCQB:OWCP

OWC PHARMACEUTICAL RESEARCH OTCQB:OWCP OWC PHARMACEUTICAL RESEARCH OTCQB:OWCP Disclaimer This document details business information of OWC Pharmaceuticals Research Corp and/or our wholly-owned Israeli subsidiary, One World Cannabis Ltd. (collectively,

More information

Investment in MGC Pharmaceuticals

Investment in MGC Pharmaceuticals Investment in MGC Pharmaceuticals Investor Presentation May 2015 Disclaimer This presentation has been prepared by Erin Resources Limited ( Company ). It does not purport to contain all the information

More information

OWC Pharmaceutical Research Corp. (OTCQB: OWCP)

OWC Pharmaceutical Research Corp. (OTCQB: OWCP) OWC Pharmaceutical Research Corp. (OTCQB: OWCP) is a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, was featured in the comments of its Advisory

More information

COMPANY PRESENTATION JULY Bob Bechard Executive Vice-President Corporate Development & Licensing

COMPANY PRESENTATION JULY Bob Bechard Executive Vice-President Corporate Development & Licensing COMPANY PRESENTATION JULY 2018 Bob Bechard Executive Vice-President Corporate Development & Licensing Forward Looking Statements Some statements in this release may contain forward-looking information.

More information

For personal use only

For personal use only ASX RELEASE (23 rd March 2018) AGM PowerPoint Presentaion In accordance with the requirements of Listing Rule 3.1 we submit the attached material being distributed at the Company s Annual General Meeting

More information

SPECIALTY MEDICAL CANNABIS COMPANY

SPECIALTY MEDICAL CANNABIS COMPANY SPECIALTY MEDICAL CANNABIS COMPANY TSX Venture: RVV OTCQB: RVVTF Corporate Presentation - August 2018 ReviveThera.com Revive Therapeutics Ltd. Office: 905-605-5535 E-mail: info@revivethera.com Forward

More information

Investor Presentation

Investor Presentation ASX:THC B u i l d i n g a M e d i c i n a l C a n n a b i s B u s i n e s s Investor Presentation November 2017 DISCLAIMER The material in this presentation (material) is not and does not constitute an

More information

MEDICAL CANNABIS COMPANY

MEDICAL CANNABIS COMPANY MEDICAL CANNABIS COMPANY TSX Venture: RVV OTCQB: RVVTF Corporate Presentation - June 2018 ReviveThera.com Revive Therapeutics Ltd. Office: 905-605-5535 E-mail: info@revivethera.com Forward looking statements

More information

For personal use only

For personal use only 28 May 2015 PYL AND MMJ ON TRACK FOR REVENUES IN JULY Highlights: Production of MMJ s GMP-produced CBD food supplement capsules commenced 25 May 2015 Capsules to be branded and sold as Sativol TM Sativol

More information

COMPANY PRESENTATION. Bernard Fortier, CEO

COMPANY PRESENTATION. Bernard Fortier, CEO COMPANY PRESENTATION Bernard Fortier, CEO Forward Looking Statements Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address

More information

Investor presentation. Bioshares Biotech Summit July 2017

Investor presentation. Bioshares Biotech Summit July 2017 Investor presentation Bioshares Biotech Summit 2017 22 July 2017 1 Disclaimer Some of the information in this presentation may refer to Dimerix Limited ( Dimerix or the Company ) based on information available

More information

TSX Venture: RVV OTCQB: RVVTF

TSX Venture: RVV OTCQB: RVVTF TSX Venture: RVV OTCQB: RVVTF Corporate Presentation November 2017 Revive Therapeutics Ltd. Office: 905-605-5535 E-mail: info@revivethera.com FORWARD LOOKING STATEMENTS Certain statements contained in

More information

For personal use only

For personal use only Investor Update - March 2017 DISCLAIMER This presentation has been prepared by MGC Pharmaceuticals Limited ( Company ). It does not purport to contain all the information that a prospective investor may

More information

AXIM Biotechnologies Reports Year End 2017 Results

AXIM Biotechnologies Reports Year End 2017 Results March 19, 2018 AXIM Biotechnologies Reports Year End 2017 Results NEW YORK, March 19, 2018 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC:AXIM), a world leader in cannabinoid research

More information

www. isotopeworld.com Advanced Medical Isotope Corporation

www. isotopeworld.com Advanced Medical Isotope Corporation www. isotopeworld.com Advanced Medical Isotope Corporation www. isotopeworld.com James C. Katzaroff Founder, CEO, Chairman December 5, 2016 Safe Harbor Statement This Overview contains forward-looking

More information

SPECIALTY MEDICAL CANNABIS COMPANY

SPECIALTY MEDICAL CANNABIS COMPANY SPECIALTY MEDICAL CANNABIS COMPANY TSX Venture: RVV OTCQB: RVVTF Corporate Presentation - August 2018 ReviveThera.com Revive Therapeutics Ltd. Office: 905-605-5535 E-mail: info@revivethera.com Forward

More information

Botanical Division Update Europe and Australia

Botanical Division Update Europe and Australia 3 July 2017 ASX Code: MXC Botanical Division Update Europe and Australia In the Czech Republic, over 470 medicinal cannabis plants have been successfully transferred to the Company s 1,000m 2 outdoor greenhouse

More information

TSX Venture: RVV OTCQB: RVVTF

TSX Venture: RVV OTCQB: RVVTF TSX Venture: RVV OTCQB: RVVTF The image part with relationship ID rid3 was not found in the file. 2017 Annual General and Special Meeting of Shareholders December 19, 2017 Revive Therapeutics Ltd. Office:

More information

N a s d a q : I N S Y

N a s d a q : I N S Y N a s d a q : I N S Y 0 Safe Harbor Statement This presentation contains both historical information and forward-looking statements. Forward-looking statements are based on management's current expectations

More information

PHYTOTECH, FIRST MEDICAL CANNABIS COMPANY TO LIST ON THE ASX

PHYTOTECH, FIRST MEDICAL CANNABIS COMPANY TO LIST ON THE ASX 22 January 2015 PHYTOTECH, FIRST MEDICAL CANNABIS COMPANY TO LIST ON THE ASX Highlights Led by a highly qualified, specialised and experienced medical and corporate team First medical grade cannabis company

More information

TSX Venture: RVV OTCQB: RVVTF

TSX Venture: RVV OTCQB: RVVTF TSX Venture: RVV OTCQB: RVVTF Corporate Presentation February 2018 Revive Therapeutics Ltd. Office: 905-605-5535 E-mail: info@revivethera.com FORWARD LOOKING STATEMENTS Certain statements contained in

More information

Delivering high quality, cost effective cannabinoid medicines to patients (ASX:AC8) September 2018

Delivering high quality, cost effective cannabinoid medicines to patients (ASX:AC8) September 2018 Delivering high quality, cost effective cannabinoid medicines to patients (ASX:AC8) September 2018 Disclaimer This presentation has been prepared by AusCann Group Holdings Ltd ACN 008 095 207 ( Company

More information

TSX Venture: RVV OTCQB: RVVTF

TSX Venture: RVV OTCQB: RVVTF TSX Venture: RVV OTCQB: RVVTF Corporate Presentation June 2018 Revive Therapeutics Ltd. Office: 905-605-5535 E-mail: info@revivethera.com FORWARD LOOKING STATEMENTS Certain statements contained in this

More information

Avenue Therapeutics, Inc. August 2016

Avenue Therapeutics, Inc. August 2016 Avenue Therapeutics, Inc. August 2016 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward looking statements within the meaning of the safe

More information

SAMPLE. Syringes and Needles Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to Reference Code: GDME0166BDB

SAMPLE. Syringes and Needles Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to Reference Code: GDME0166BDB Syringes and Needles Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018 Reference Code: GDME0166BDB Publication Date: January 2013 GlobalData. This report is a licensed product

More information

Investor Presentation May 2, 2017

Investor Presentation May 2, 2017 CSE: TBP OTC: GRPOF Investor Presentation May 2, 2017 Forward Looking Statements This presentation contains certain forward-looking statements that may involve a number of risks and uncertainties. Actual

More information

PROACTIVE INVESTOR PRESENTATION

PROACTIVE INVESTOR PRESENTATION www.thcl.com.au ASX RELEASE (16 th May 2017) PROACTIVE INVESTOR PRESENTATION The Hydroponics Company Limited (ASX: THC) is pleased to advise that Dr Andrew Beehag, Chief Executive Officer of Canndeo Limited,

More information

SAMPLE. Sterilization and Disinfectant Equipment Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018

SAMPLE. Sterilization and Disinfectant Equipment Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018 Sterilization and Disinfectant Equipment Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018 Reference Code: GDME0165BDB Publication Date: January 2013 GlobalData. This report

More information

E N H A N C IN G HE A LTH THRO U GH CANNABIS S CIENCE

E N H A N C IN G HE A LTH THRO U GH CANNABIS S CIENCE I N V E S T O R P R E S E N TAT I O N Q 4 2 0 1 6 TM HEALTH THERAPEUTICS E N H A N C IN G HE A LTH THRO U GH CANNABIS S CIENCE T S X. V: E M H DISCLAIMER THE STATEMENTS MADE IN THIS PRESENTATION MAY INCLUDE

More information

Global Legal Cannabis Market: Size, Trends & Forecasts ( ) September 2018

Global Legal Cannabis Market: Size, Trends & Forecasts ( ) September 2018 Global Legal Cannabis Market: Size, Trends & Forecasts (2018-2022) September 2018 Global Legal Cannabis Market: Coverage Executive Summary and Scope Introduction/Market Overview Global Market Analysis

More information

Corporate Presentation. October 2017

Corporate Presentation. October 2017 AEPP Breakthrough technology for women s cancers Corporate Presentation October 2017 Oncolix 2017 1 Safe Harbor Certain of the statements and the projections set forth in this presentation constitute forward-looking

More information

Pierre Legault CEO June 2, 2014

Pierre Legault CEO June 2, 2014 April 2012 Pierre Legault CEO June 2, 2014 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking

More information

HILLENBRAND INDUSTRIES INC

HILLENBRAND INDUSTRIES INC HILLENBRAND INDUSTRIES INC FORM 8-K (Unscheduled Material Events) Filed 2/17/2004 For Period Ending 2/13/2004 Address 700 STATE ROUTE 46 E BATESVILLE, Indiana 47006-8835 Telephone 812-934-7000 CIK 0000047518

More information

Better Diagnostics for Life

Better Diagnostics for Life NASDAQ: NMRD Better Diagnostics for Life Corporate Presentation November 2018 Forward-Looking Statement This presentation includes forward-looking statements that are subject to many risks and uncertainties.

More information

Research: Medical Cannabis

Research: Medical Cannabis Research: Medical Cannabis Background The hemp plant Cannabis sativa (cannabis) is commonly known as marijuana and can be used as a therapy to alleviate symptoms such as pain and fatigue caused by chronic

More information

World leader in navigated, non-invasive brain stimulation therapy and diagnosis

World leader in navigated, non-invasive brain stimulation therapy and diagnosis World leader in navigated, non-invasive brain stimulation therapy and diagnosis Martin Jamieson CEO & Chairman of the Board Nexstim Plc Mikko Karvinen CFO Nexstim Plc Corporate Presentation, BioTrinity,

More information

Avenue Therapeutics, Inc. September 2016

Avenue Therapeutics, Inc. September 2016 Avenue Therapeutics, Inc. September 2016 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward looking statements within the meaning of the

More information

The Verde Mountain Fund offers a unique opportunity to gain early entry into one of the fastest growing industries in a generation.

The Verde Mountain Fund offers a unique opportunity to gain early entry into one of the fastest growing industries in a generation. The Verde Mountain Fund offers a unique opportunity to gain early entry into one of the fastest growing industries in a generation. The Verde Mountain Fund offers a unique investment opportunity for both

More information

Corporate Presentation September 2017

Corporate Presentation September 2017 Enhancing Life Through Nature TSX: CZO Corporate Presentation September 2017 www.ceapro.com 2 Forward Looking Statements This presentation contains forward-looking statements. Various factors could cause

More information

Avenue Therapeutics, Inc. May 2017

Avenue Therapeutics, Inc. May 2017 Avenue Therapeutics, Inc. May 2017 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward looking statements within the meaning of the safe

More information

Oragenics Shareholder Update

Oragenics Shareholder Update January 4, 2017 Oragenics Shareholder Update Advances Drug Development Programs Focused on Conditions with Significant Unmet Medical Needs TAMPA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (NYSE MKT:OGEN.BC),

More information

Corporate Presentation December 2017

Corporate Presentation December 2017 Enhancing Life Through Nature TSX: CZO Corporate Presentation December 2017 www.ceapro.com 2 Forward Looking Statements This presentation contains forward-looking statements. Various factors could cause

More information

Global Dravet Syndrome Market: Industry Analysis & Outlook ( )

Global Dravet Syndrome Market: Industry Analysis & Outlook ( ) Industry Research by Koncept Analytics Global Dravet Syndrome Market: Industry Analysis & Outlook ----------------------------------------- February 2019 Global Dravet Syndrome Market: Industry Analysis

More information

Developing cannabinoid based pharmaceuticals (TASE: THXBY; OTCQB: THXBY) Corporate Presentation February 2016

Developing cannabinoid based pharmaceuticals (TASE: THXBY; OTCQB: THXBY) Corporate Presentation February 2016 Developing cannabinoid based pharmaceuticals (TASE: THXBY; OTCQB: THXBY) Corporate Presentation February 2016 Safe Harbor Statement This presentation has been prepared for informational purposes only and

More information

SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS

SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS SPHERIX Investor Relations Phone: (301) 897-2564 Email: info@spherix.com SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS BETHESDA, MD, May 21, 2010 - Spherix Incorporated (NASDAQ CM: SPEX), an innovator

More information

Leading Cannabinoid Patient Care in Canada. Corporate Presentation July 2017 TSXV: CMM OTCQB: CAMDF

Leading Cannabinoid Patient Care in Canada. Corporate Presentation July 2017 TSXV: CMM OTCQB: CAMDF Leading Cannabinoid Patient Care in Canada Corporate Presentation July 2017 TSXV: CMM OTCQB: CAMDF Forward Looking Statements Except for historical information, this presentation contains forward-looking

More information

XXII: CTP Summarizes Scientific Case for Limiting Nicotine in Cigarettes. Company Update October 15, 2018 Industrial & Consumer Technology

XXII: CTP Summarizes Scientific Case for Limiting Nicotine in Cigarettes. Company Update October 15, 2018 Industrial & Consumer Technology Company Update Industrial & Consumer Technology (XXII - $2.81 - Buy) COMPANY NOTE JAMES McILREE, CFA, Senior Research Analyst, +1-646-465-9034 jmcilree@chardan.com Sales and trading 7 a.m. to 7 p.m. ET,

More information

Advancing Pancreatic & Liver Cancer Treatment

Advancing Pancreatic & Liver Cancer Treatment ASX.OSL Advancing Pancreatic & Liver Cancer Treatment Australian Biotech Invest 2017 October 24 th Melbourne 1 Important notice This Presentation has been prepared by Ltd (ASX:OSL) (OncoSil or the Company)

More information

BIO INVESTOR FORUM PRESENTATION

BIO INVESTOR FORUM PRESENTATION TSX-V: TBP OTC: TBPMF BIO INVESTOR FORUM PRESENTATION Bob Béchard VP Business Development 17 OCTOBRE 2017 Forward Looking Statements This presentation contains certain forward-looking statements that may

More information

CEOCFO Magazine. Chris Wagner Chief Executive Officer. Emerald Health Therapeutics, Inc. (TSXV: EMH; OTCQX: EMHTF)

CEOCFO Magazine. Chris Wagner Chief Executive Officer. Emerald Health Therapeutics, Inc. (TSXV: EMH; OTCQX: EMHTF) CEOCFO Magazine ceocfointerviews.com All rights reserved Issue: March 19, 2018 Q&A with Chris Wagner, CEO of Emerald Health Therapeutics, Inc. a Health Canada Licensed Producer of Medical Cannabis allowing

More information

BRIC Transurethral Resection of the Prostate (TURP) Procedures Outlook to 2020

BRIC Transurethral Resection of the Prostate (TURP) Procedures Outlook to 2020 BRIC Transurethral Resection of the Prostate (TURP) Procedures Outlook Reference Code: GDMECR0130PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables...

More information

AMERICAN ROOTS. GLOBAL REACH CSE: TGIF FWB: 1QF OTC: TGIFF

AMERICAN ROOTS. GLOBAL REACH CSE: TGIF FWB: 1QF OTC: TGIFF AMERICAN ROOTS. GLOBAL REACH 1 Friday Night Inc. is focused on strengthening and expanding its current cannabis operations and consultancy, and is positioning itself to thrive in the rapidly evolving cannabis

More information

For personal use only

For personal use only 13 February 2018 Creso reports strong progress with construction of its Canadian medicinal cannabis production facility in Nova Scotia Highlights: Site works at Creso s Canadian medicinal cannabis production

More information

Corporate Update. NASDAQ: GALT April 9, 2018

Corporate Update. NASDAQ: GALT  April 9, 2018 Corporate Update April 9, 2018 NASDAQ: GALT www.galectintherapeutics.com Forward-Looking Statements This presentation contains, in addition to historical information, forward-looking statements within

More information

RespireRx Pharmaceuticals Inc. Executives Presenting at the International Cannabinoid Derived Pharmaceuticals Summit

RespireRx Pharmaceuticals Inc. Executives Presenting at the International Cannabinoid Derived Pharmaceuticals Summit RespireRx Pharmaceuticals Inc. Executives Presenting at the International Cannabinoid Derived Pharmaceuticals Summit December 11 12, 2018 Workshops, December 10, 2018 The Revere Hotel 200 Stuart St., Boston,

More information

Sumitomo Dainippon Pharma to Acquire Tolero Pharmaceuticals, Inc. (US Biotechnology Company)

Sumitomo Dainippon Pharma to Acquire Tolero Pharmaceuticals, Inc. (US Biotechnology Company) December 21, 2016 Sumitomo Dainippon Pharma Co., Ltd. Sumitomo Dainippon Pharma to Acquire Tolero Pharmaceuticals, Inc. (US Biotechnology Company) Sumitomo Dainippon Pharma Co., Ltd. (Head office: Osaka,

More information

Asia-Pacific Bariatric Surgery Devices Market Outlook to 2020

Asia-Pacific Bariatric Surgery Devices Market Outlook to 2020 Asia-Pacific Bariatric Surgery Devices Market Outlook to 2020 Reference Code: GDMECR0195DB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 4 1.2 List

More information

which has been used to help the treatment of epilepsy, seizures, alleviate neuropathic pain and muscular dystrophy.

which has been used to help the treatment of epilepsy, seizures, alleviate neuropathic pain and muscular dystrophy. News Release April 10, 2018, Kelowna, BC Marapharm Ventures Inc. To Introduce Organic CBD Health and Wellness Products To Be Featured In Its California Dispensary Marapharm Ventures Inc. (CSE: MDM) (OTCQX:

More information

34 th Annual J.P. Morgan Healthcare Conference

34 th Annual J.P. Morgan Healthcare Conference JANUARY 2016 34 th Annual J.P. Morgan Healthcare Conference [ 1 ] Forward Looking Statements SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS In addition to historical information, this presentation contains

More information

EU5 Bariatric Surgery Procedures Outlook to 2020

EU5 Bariatric Surgery Procedures Outlook to 2020 EU5 Bariatric Surgery Procedures Outlook to 2020 Reference Code: GDMECR0089PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3 1.2 List of Figures...

More information

Neovasc Inc. Alexei Marko, CEO. January 2012 OneMedForum

Neovasc Inc. Alexei Marko, CEO. January 2012 OneMedForum Neovasc Inc. Alexei Marko, CEO January 2012 OneMedForum 2 Forward-Looking Statements Statements contained herein that are not based on historical or current fact, including without limitation statements

More information

Media Kit. September 2017

Media Kit. September 2017 Media Kit September 2017 About Pear Pear Therapeutics is the leader in FDA-cleared Prescription Digital Therapeutics. The company s approach is to integrate clinically-validated software applications with

More information

ALLIANCE GROWERS. Investor Presentation Chilco Design Studio Inc.

ALLIANCE GROWERS. Investor Presentation Chilco Design Studio Inc. ALLIANCE GROWERS Investor Presentation 2018 2018 Chilco Design Studio Inc. Forward-Looking Statements Disclaimer Certain information regarding the company contained herein may constitute forward-looking

More information

For personal use only

For personal use only Developing high quality, cost effective cannabinoid medicines Investor Presentation March 2019 Disclaimer 3 This presentation has been prepared by AusCann Group Holdings Ltd ACN 008 095 207 ( Company ).

More information

Q3 18 Earnings Supplemental Slides

Q3 18 Earnings Supplemental Slides (Nasdaq: INSY) Q3 18 Earnings Supplemental Slides November 5, 2018 Safe-Harbor Statement This presentation contains both historical information and forward-looking statements. Forward-looking statements

More information

Asia-Pacific Endoscopic Retrograde Cholangiopancreatography (ERCP) Procedures Outlook to 2020

Asia-Pacific Endoscopic Retrograde Cholangiopancreatography (ERCP) Procedures Outlook to 2020 Asia-Pacific Endoscopic Retrograde Cholangiopancreatography (ERCP) Reference Code: GDMECR0107PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3

More information

IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics

IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Rodman & Renshaw 19 th Annual Global Investment Conference Michael R. Garone, Principal Executive Officer and CFO Forward-Looking

More information

Shareholder Presentation Annual Meeting 2018

Shareholder Presentation Annual Meeting 2018 Shareholder Presentation Annual Meeting 2018 FY 18 HIGHLIGHTS Strong sales growth of 2 nd Gen TruScreen to China commenced during 4 th quarter. (50% of the year s sales were generated in the fourth quarter)

More information

Israel Makov President and Chief Executive Officer Teva

Israel Makov President and Chief Executive Officer Teva Israel Makov President and Chief Executive Officer Israel Makov has been the President and Chief Executive Officer of since April 2002. Previously he served as 's Chief Operating Officer from January 1,

More information

Dainippon Pharmaceutical and Sumitomo Pharmaceuticals Finalize Merger Agreement

Dainippon Pharmaceutical and Sumitomo Pharmaceuticals Finalize Merger Agreement For immediate release April 28, 2005 Dainippon Pharmaceutical and Sumitomo Pharmaceuticals Finalize Merger Agreement Dainippon Pharmaceutical Co., Ltd. Sumitomo Pharmaceuticals Co., Ltd. Dainippon Pharmaceutical

More information

February 23, Q4 and Year-End 2016 Financial Results

February 23, Q4 and Year-End 2016 Financial Results February 23, 2017 Q4 and Year-End 2016 Financial Results 2 RETHINKING CNS Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Jim Doherty, Ph.D.,

More information

August 7, Q Financial Results

August 7, Q Financial Results August 7, 2018 Q2 2018 Financial Results 1 Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Steve Kanes, M.D., Ph.D., Chief Medical Officer

More information

Enhancing Life Through Nature

Enhancing Life Through Nature Enhancing Life Through Nature TSX: CZO Corporate Presentation March 2018 www.ceapro.com 2 Forward Looking Statements This presentation contains forward-looking statements. Various factors could cause actual

More information

GLOBAL GENETIC TESTING MARKET. Growth Trends & Forecasts. mordorintelligence.com

GLOBAL GENETIC TESTING MARKET. Growth Trends & Forecasts. mordorintelligence.com GLOBAL GENETIC TESTING MARKET 2014-2020 Growth Trends & Forecasts mordorintelligence.com TABLE OF CONTENTS 1 Introduction 1.1 Report Description 1.2 Research Methodology 2. Genetic Testing Market Overview

More information

AStoryofSunPharmaceuticalsLaboratoriesGoingGlobal

AStoryofSunPharmaceuticalsLaboratoriesGoingGlobal Global Journal of HUMANSOCIAL SCIENCE: E Economics Volume 18 Issue 4 Version 1.0 Type: Double Blind Peer Reviewed International Research Journal Publisher: Global Journals Online ISSN: 2249460x & Print

More information

- Plans Commercial Launch of three dosing options for Excellagen in pre-filled syringes

- Plans Commercial Launch of three dosing options for Excellagen in pre-filled syringes Generex Biotechnology Subsidiary Olaregen Therapeutix Inc. Plans Launch of FDA Cleared Excellagen Wound Conforming Gel Matrix with Three Dosage Options - Plans Commercial Launch of three dosing options

More information

Equity Research. Industry Update. Key Takeaways The Impact of The Opioid Epidemic on The Pain Management Landscape

Equity Research. Industry Update. Key Takeaways The Impact of The Opioid Epidemic on The Pain Management Landscape Member FINRA and SIPC Equity Research November 17, 2017 Healthcare Industry Update Key Takeaways The Impact of The Opioid Epidemic on The Pain Management Landscape Conclusions We hosted a key opinion leader

More information

Tamsulosin Hydrochloride 0.4 mg Capsule

Tamsulosin Hydrochloride 0.4 mg Capsule Tamsulosin Hydrochloride 0.4 mg Capsule, Tamsulosin Hydrochloride 0.4 mg Capsule India, Tamsulosin Hydrochloride 0.4 mg Capsule manufacturers India, side effects Tamsulosin Hydrochloride 0.4 mg Capsule

More information

Your Contacts. EMA ODD is an important regulatory milestone for avelumab in metastatic Merkel cell carcinoma (MCC)

Your Contacts. EMA ODD is an important regulatory milestone for avelumab in metastatic Merkel cell carcinoma (MCC) Your Contacts News Release Merck KGaA, Darmstadt, Germany Media: Gangolf Schrimpf +49 6151 72 9591 Investor Relations: +49 6151 72 3321 Pfizer Inc., New York, USA Media: Lisa O Neill +44 1737 331536 Investor

More information

Developing cannabinoid based pharmaceuticals (TASE: THXBY; OTCQB: THXBY) Corporate Presentation September 2015

Developing cannabinoid based pharmaceuticals (TASE: THXBY; OTCQB: THXBY) Corporate Presentation September 2015 Developing cannabinoid based pharmaceuticals (TASE: THXBY; OTCQB: THXBY) Corporate Presentation September 2015 Safe Harbor Statement This presentation has been prepared for informational purposes only

More information

For personal use only

For personal use only Cancer killing viruses Oncolytic Virotherapeutics Bryan Dulhunty Managing Director Bell Potter Life Sciences Conference Building a Global Profile May 2102 bryan.dulhunty@viralytics.com www.viralytics.com

More information

GW Pharmaceuticals plc. Investor Presentation August 2014

GW Pharmaceuticals plc. Investor Presentation August 2014 GW Pharmaceuticals plc Investor Presentation August 2014 Forward Looking Statements and Disclaimer This presentation contains forward-looking statements. Some of the matters discussed concerning our operations

More information

China Cranio Maxillofacial Fixation (CMF) Market Outlook to 2020

China Cranio Maxillofacial Fixation (CMF) Market Outlook to 2020 China Cranio Maxillofacial Fixation (CMF) Market Outlook to 2020 Reference Code: GDMECC0079DB Publication Date: March 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 4 1.2

More information

INVESTOR PRESENTATION

INVESTOR PRESENTATION INVESTOR PRESENTATION JUNE 2016 OTCQB:CANN ABOUT General Cannabis Corporation (GCC) is the all-in-one resource for the highest quality service providers available to the regulated Cannabis Industry. We

More information

THE COMPLETE CBD GUIDE

THE COMPLETE CBD GUIDE THE COMPLETE CBD GUIDE WHAT IS CBD (CANNABIDIOL)? 2 WHERE DOES CBD COME FROM? 3 HOW DOES CBD WORK IN THE BODY? 4 HOW MUCH CBD DO I TAKE? 5-6 CBD OIL VS. HEMP OIL 7 CBD NOT THC 8 THE BENEFITS OF CBD 9 PETS

More information

Calliditas Therapeutics Q2 Report Webcast August 16, 2018, 10:00 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO

Calliditas Therapeutics Q2 Report Webcast August 16, 2018, 10:00 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO Calliditas Therapeutics Q2 Report 2018 Webcast August 16, 2018, 10:00 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO Disclaimer Important information This presentation may contain certain

More information

Committed to Conquering Heart Failure

Committed to Conquering Heart Failure Committed to Conquering Heart Failure January 2018 Cardiol is focused on the research and development of nanotherapeutics for the treatment of heart failure and other inflammatory conditions. Market Opportunity

More information

CTT Pharmaceutical Holdings, Inc Novel Drug Delivery Technologies

CTT Pharmaceutical Holdings, Inc Novel Drug Delivery Technologies CTT Pharmaceutical Holdings, Inc Novel Drug Delivery Technologies Forward Looking Statements Except for the historical information contained herein, the matters discussed in this PPT release are forward

More information

Developing Xanamem for Alzheimer s Dementia

Developing Xanamem for Alzheimer s Dementia Developing Xanamem for Alzheimer s Dementia Dr. Bill Ketelbey CEO, Actinogen Medical Investor Presentation March 2015 Forward Statements This presentation has been prepared by Actinogen Limited. ( Actinogen

More information

Aviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES

Aviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES Aviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES October 30, 2017 Safe Harbor This presentation contains forward-looking statements about

More information

For personal use only. Investor Presentation Nov

For personal use only. Investor Presentation Nov Investor Presentation Nov 2016 www.zeldatherapeutics.com Disclaimer and Important Notice 2 Disclaimer This presentation has been prepared by Zelda Therapeutics Pty Ltd ACN 607 538 876 ( Company ). It does

More information

Eli Lilly and Company Tailored Therapeutics and Diagnostics

Eli Lilly and Company Tailored Therapeutics and Diagnostics Eli Lilly and Company Tailored Therapeutics and Diagnostics The views and opinions expressed herein and/or during the accompanying discussion are those of the author and do not necessarily represent the

More information

19 th. Letter from our CEO. Letter from our CEO CATEGORIES RECENT POSTS. 1 of 5 02/06/ :59 AM AUG. In the News (16)

19 th. Letter from our CEO. Letter from our CEO CATEGORIES RECENT POSTS. 1 of 5 02/06/ :59 AM AUG. In the News (16) Letter from our CEO You Are Here: Sciences Pharmaceutical Neuroprotection Company News Letter from our CEO AUG 19 th In News, Press Release Letter from our CEO Last week the U.S. Drug Enforcement Administration

More information

Environmental, Health and Safety

Environmental, Health and Safety Environmental, Health and Safety Codes of Practice The Environmental, Health and Safety (EHS) Codes of Practice set forth Zimmer EHS requirements for our business functions and facilities worldwide. In

More information

Mexico Ostomy Drainage Bags Market Outlook to 2020

Mexico Ostomy Drainage Bags Market Outlook to 2020 Mexico Ostomy Drainage Bags Market Outlook to 2020 Reference Code: GDMECC0990DB Publication Date: October 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 4 1.2 List of Figures...

More information

Better Diagnostics for Life

Better Diagnostics for Life NASDAQ: NMRD Better Diagnostics for Life Corporate Presentation December 2018 Forward-Looking Statement This presentation includes forward-looking statements that are subject to many risks and uncertainties.

More information

QiG INS Conference May 22, 2011

QiG INS Conference May 22, 2011 Strategy & Vision Growth Electrochem Medical Device Evolution QiG Cardio vascular QiG INS Conference May 22, 2011 Greatbatch Medical Neuro modulation 1 GREATBATCH TODAY 2010 Revenue by Product Line NYSE:

More information

Unique Pharmaceutical Cannabinoid Technologies Developed in Israel

Unique Pharmaceutical Cannabinoid Technologies Developed in Israel Unique Pharmaceutical Cannabinoid Technologies Developed in Israel (TASE: THXBY; OTCQB: THXBY) July 2016 Safe Harbor Statement presentation has been prepared for informational purposes only and does not

More information

MagSense Technology. For personal use only. Company Overview. A New Clinical Diagnostic Technology for Targeted Early Detection of Cancer

MagSense Technology. For personal use only. Company Overview. A New Clinical Diagnostic Technology for Targeted Early Detection of Cancer MagSense Technology A New Clinical Diagnostic Technology for Targeted Early Detection of Cancer Company Overview October 2017 ASX:IBX www.imagionbiosystems.com Disclaimer This presentation has been prepared

More information

GENETIC TECHNOLOGIES LIMITED DISEASE RISK ASSESSMENT ON A GLOBAL SCALE

GENETIC TECHNOLOGIES LIMITED DISEASE RISK ASSESSMENT ON A GLOBAL SCALE GENETIC TECHNOLOGIES LIMITED DISEASE RISK ASSESSMENT ON A GLOBAL SCALE Forward Looking Statements This presentation may contain forward-looking statements within the meaning of Section 27A of the U.S.

More information